Sodium Bicarbonate → (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dimethylbenzyl)-4-[2-[2-(3,3-dimethylmorpholino)ethoxy]ethyl]piperazine dihydrochloride

HRID 584186ノート

反応式

HRID 584186 の反応式
[ClH:1].[CH3:2][C:3]1([CH3:9])[CH2:8][O:7][CH2:6][CH2:5][NH:4]1.[F:10][C:11]([F:46])([F:45])[C:12]1[CH:13]=[C:14]([CH:38]=[C:39]([C:41]([F:44])([F:43])[F:42])[CH:40]=1)[C:15]([N:17]1[CH2:22][CH2:21][N:20]([CH2:23][CH2:24][O:25][CH2:26][CH:27]=O)[CH2:19][C@H:18]1[CH2:29][C:30]1[CH:35]=[CH:34][C:33]([CH3:36])=[C:32]([CH3:37])[CH:31]=1)=[O:16].C(O[BH-](OC(=O)C)OC(=O)C)(=O)C.[Na+].C(=O)(O)[O-].[Na+]>ClCCl.C(N(CC)CC)C>[ClH:1].[ClH:1].[F:46][C:11]([F:10])([F:45])[C:12]1[CH:13]=[C:14]([CH:38]=[C:39]([C:41]([F:42])([F:43])[F:44])[CH:40]=1)[C:15]([N:17]1[CH2:22][CH2:21][N:20]([CH2:23][CH2:24][O:25][CH2:26][CH2:27][N:4]2[CH2:5][CH2:6][O:7][CH2:8][C:3]2([CH3:9])[CH3:2])[CH2:19][C@H:18]1[CH2:29][C:30]1[CH:35]=[CH:34][C:33]([CH3:36])=[C:32]([CH3:37])[CH:31]=1)=[O:16]

参加物

7

反応物 4

HCID 516892Sodium BicarbonateHCID 5049666Sodium triacetoxyborohydrideHCID 223428633,3-Dimethylmorpholine hydrochlorideHCID 86588511(2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dimethylbenzyl)-4-[2-(formylmethoxy)ethyl]piperazine

生成物 1

HCID 86596425(2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dimethylbenzyl)-4-[2-[2-(3,3-dimethylmorpholino)ethoxy]ethyl]piperazine dihydrochloride収率 132.2%

試薬・触媒・溶媒 2

HCID 6344Dichloromethane溶媒HCID 8471Triethylamine溶媒

実験手順

To a stirred mixture of 3,3-dimethylmorpholine hydrochloride (63 mg) and triethylamine (42 mg) in dichloromethane (5 ml) were added (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dimethylbenzyl)-4-[2-(formylmethoxy)ethyl]piperazine (200 mg) and sodium triacetoxyborohydride (120 mg) at room temperature. The resulting mixture was stirred for 1 hour and then treated with aqueous sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. After evaporation of the solvent, the residue was purified by column chromatography on silica gel using dichloromethanemethanol (10:1) as eluent and treated with 4N hydrogen chloride in ethyl acetate to give (2R)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-(3,4-dimethylbenzyl)-4-[2-[2-(3,3-dimethylmorpholino)ethoxy]ethyl]piperazine dihydrochloride (193 mg) as a powder.

後処理

  1. customThe organic layer was separated
  2. dry with materialdried over magnesium sulfate
  3. customAfter evaporation of the solvent
  4. customthe residue was purified by column chromatography on silica gel using dichloromethanemethanol (10:1) as eluent
  5. additiontreated with 4N hydrogen chloride in ethyl acetate

出典と根拠

ORDレコード
ord-d30468478fb7410c9bd54d8e93ab40a1
出典データセット
uspto-grants-2005_08
特許番号
US06924278B2

反応ノート

読み込み中…